Category Archives: Supply Chain

China Supply Chain Progress Still Hampered by Corruption, Pollution, Working Conditions

Supply chains risks in China still include extremely high levels of corruption, environmental pollution issues and slow working conditions reforms, according to new analysis from Sedex.
Also posted in Emerging Markets, Global | Tagged , , , | Leave a comment

Track-and-Trace Not Enough to Halt Drug Counterfeiters

Despite recent legislation to establish a more secure pharmaceutical supply chain to deliver high quality, approved medicines to American patients, efforts to block the import of substandard, fraudulent, and counterfeit drugs remains an uphill fight. Criminals are expanding from “lifestyle” drugs to widely used anti-cholesterol and cancer medicines, attracted by huge profits and low risks […]
Also posted in FDA, Regulatory, Safety | Tagged , , , , , | Leave a comment

Drug Shortages Continue to Plague Health Care System

Despite notable successes in preventing and mitigating short supplies of important medicines, the drug shortage crisis still disrupts medical treatment and gives drug manufacturers a bad name. The Food and Drug Administration is doing a better job of identifying potential shortage situations and implementing relief strategies, but many supply problems continue to limit treatment options […]
Also posted in FDA, Legal, Manufacturing, Safety | Tagged , , , , , , | Leave a comment

Big Pharma's Second Life

Can big pharma solve its fixed cost problem by going virtual? Not entirely, but drug companies can get more out of their CRO partners by treating them less like avatars and more like equals, according to conference-goers at a CBI event in The Triangle. The problem with overbearing project mangers on the sponsor side of […]
Also posted in Biotech, People, R&D, Strategy | Tagged , , , , , | Leave a comment

The Little Orphan That Could: How Alexion is Going Global

Since the initial FDA approval of its flagship orphan drug Soliris in 2007, Alexion Pharmaceuticals has done well for itself as a small biotech firm that focuses on ultra-rare disease. So well in fact, that instead of partnering, the company has taken global expansion into its own hands. Apart from a pipeline that includes asfotase […]
Also posted in Biotech, Global, Manufacturing, Market Access, Orphan Drugs, Strategy | Tagged , , , , , , , , | Leave a comment
  • Categories

  • Meta